8-K: Microbot Medical Amends At-the-Market Offering Agreement, Plans to Sell Up to $4.8 Million in Shares

Microbot Medical Inc. has amended its at-the-market offering agreement to facilitate the sale of up to $4.8 million in common stock under a new registration statement.

Summary

• Microbot Medical Inc. has updated its at-the-market (ATM) offering program by filing a prospectus supplement with the SEC on July 1, 2024.
• This supplement relates to the sale of common stock under the ATM program, which was previously registered under a 2020 registration statement.
• The company is now using a 2023 registration statement for the ATM program.
• The amendment to the sales agreement with H.C. Wainwright & Co., LLC, also dated July 1, 2024, reflects this change.
• The company may sell up to $4,819,905 of its common stock through the ATM program.
• Sales will be made through various methods, including directly on the Nasdaq Capital Market, to market makers, or in negotiated transactions.
• The company has also provided an opinion from its counsel regarding the validity of the shares offered under the ATM program.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a routine capital raising activity, which is expected for a company of this size. There are no significant positive or negative surprises.

Positives

• The company has secured a mechanism to raise up to $4.8 million in capital through the ATM program.
• The amendment to the sales agreement ensures the company can continue to utilize the ATM program under the new registration statement.
• The legal opinion provided by counsel supports the validity of the shares being offered.

Risks

• The sale of shares through the ATM program could dilute existing shareholders' ownership.
• The company's reliance on the ATM program for funding may indicate a need for additional capital.
• Market conditions could impact the company's ability to sell shares at favorable prices.

Future Outlook

The company intends to sell shares of its common stock through the ATM program as market conditions allow, with the goal of raising up to $4,819,905.

Industry Context

The use of at-the-market offerings is a common method for small-cap and micro-cap companies to raise capital, particularly in the biotech and medical device sectors. This allows for flexible funding without the need for large, dilutive offerings.

Comparison to Industry Standards

• Many small-cap biotech companies use ATM offerings to raise capital, including companies like XBiotech Inc. and Athersys Inc.
• The size of the offering, $4.8 million, is relatively small compared to some larger biotech companies, but is typical for companies of Microbot Medical's size and stage.
• The use of H.C. Wainwright as the sales agent is also common, as they specialize in working with smaller, growth-oriented companies.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company will have additional capital to fund its operations and growth initiatives.
• The company's ability to raise capital may be viewed positively by investors.

Next Steps

• The company will proceed with the sale of common stock through the ATM program.
• The company will continue to monitor market conditions to determine the timing and amount of shares to be sold.

Key Dates

Keywords

at-the-market offering, ATM program, common stock, prospectus supplement, registration statement, H.C. Wainwright, capital raise, securities offering